drugset / Trial / NCT01332188

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188

Phase 2/3 Completed 101 enrolled Aciex Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.

Timeline

Start
2011-04
Primary completion
2011-06
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetirizine Other / unclassified 0.05 % Other
Subject Cetirizine Other / unclassified 0.1 % Other
Subject Cetirizine Other / unclassified 0.24 % Other

Indications